Literature DB >> 9146767

One-week triple therapy with omeprazole, amoxycillin and tinidazole for Helicobacter pylori infection: the significance of imidazole resistance.

J C Thijs1, A A Van Zwet, W J Thijs, E J Van der Wouden, A Kooy.   

Abstract

BACKGROUND: Triple therapy involving a proton pump inhibitor and two antibiotics has been suggested as an effective treatment for Helicobacter pylori infection. The impact of imidazole resistance on the efficacy of such regimens is largely unknown.
METHODS: One hundred patients with culture proven H. pylori infection were treated with omeprazole 40 mg b.d., amoxycillin 1000 mg b.d., and tinidazole 500 mg b.d. for one week. Pre-treatment imidazole susceptibility was measured by disk diffusion. Resistance was confirmed by E-test. Eradication was assessed by endoscopy 6-8 weeks after the end of treatment. In cases of doubt a 13C-urea breath test was performed. Side-effects were scored using a semiquantitative scale.
RESULTS: H. pylori was eradicated in 95% of the patients with an imidazole-susceptible strain and in 69% of the patients with a resistant strain (P < 0.005). Significant side-effects were seen in 12%.
CONCLUSION: This proton pump inhibitor triple therapy is a simple, reasonably effective regimen with few significant side-effects. The efficacy is dependent on the susceptibility of the infecting H. pylori strain.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9146767     DOI: 10.1046/j.1365-2036.1997.155329000.x

Source DB:  PubMed          Journal:  Aliment Pharmacol Ther        ISSN: 0269-2813            Impact factor:   8.171


  9 in total

Review 1.  Regular review: treatment of Helicobacter pylori infection.

Authors:  W A de Boer; G N Tytgat
Journal:  BMJ       Date:  2000-01-01

Review 2.  A practical approach to patients with refractory Helicobacter pylori infection, or who are re-infected after standard therapy.

Authors:  U Peitz; A Hackelsberger; P Malfertheiner
Journal:  Drugs       Date:  1999-06       Impact factor: 9.546

3.  Direct detection of Helicobacter pylori resistance to macrolides by a polymerase chain reaction/DNA enzyme immunoassay in gastric biopsy specimens.

Authors:  A Marais; L Monteiro; A Occhialini; M Pina; H Lamouliatte; F Mégraud
Journal:  Gut       Date:  1999-04       Impact factor: 23.059

4.  Effect of pretreatment antibiotic resistance to metronidazole and clarithromycin on outcome of Helicobacter pylori therapy: a meta-analytical approach.

Authors:  M P Dore; G Leandro; G Realdi; A R Sepulveda; D Y Graham
Journal:  Dig Dis Sci       Date:  2000-01       Impact factor: 3.199

5.  Macrolide resistance in Helicobacter pylori: rapid detection of point mutations and assays of macrolide binding to ribosomes.

Authors:  A Occhialini; M Urdaci; F Doucet-Populaire; C M Bébéar; H Lamouliatte; F Mégraud
Journal:  Antimicrob Agents Chemother       Date:  1997-12       Impact factor: 5.191

6.  Rapid increase in the prevalence of metronidazole-resistant Helicobacter pylori in the Netherlands.

Authors:  E J van der Wouden; A A van Zwet; G D Vosmaer; J A Oom; A de Jong; J H Kleibeuker
Journal:  Emerg Infect Dis       Date:  1997 Jul-Sep       Impact factor: 6.883

Review 7.  Clinical relevance of resistant strains of Helicobacter pylori: a review of current data.

Authors:  F Mégraud; H P Doermann
Journal:  Gut       Date:  1998-07       Impact factor: 23.059

Review 8.  Omeprazole. A review of its use in Helicobacter pylori infection, gastro-oesophageal reflux disease and peptic ulcers induced by nonsteroidal anti-inflammatory drugs.

Authors:  H D Langtry; M I Wilde
Journal:  Drugs       Date:  1998-09       Impact factor: 9.546

9.  Exposure to metronidazole in vivo readily induces resistance in Helicobacter pylori and reduces the efficacy of eradication therapy in mice.

Authors:  P J Jenks; A Labigne; R L Ferrero
Journal:  Antimicrob Agents Chemother       Date:  1999-04       Impact factor: 5.191

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.